Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

PURPOSE: Significant improvement in survival outcomes has been established with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2) –positive early breast cancer treatment. However, trastuzumab may increase the risk of cardiac toxicity, and long-t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Advani, Pooja P., Ballman, Karla V., Dockter, Travis J., Colon-Otero, Gerardo, Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4980566/
https://ncbi.nlm.nih.gov/pubmed/26392097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.8413
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares